Fredag 27 December | 16:25:41 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-13 08:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2024-05-14 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Extra Bolagsstämma 2024
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-09-28 - Extra Bolagsstämma 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-12-09 - Extra Bolagsstämma 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-23 - Extra Bolagsstämma 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2021-05-11 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-08-11 - Extra Bolagsstämma 2020
2020-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-08-16 - Extra Bolagsstämma 2019
2019-05-17 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2018-05-23 - Årsstämma
2018-05-23 - Kvartalsrapport 2018-Q1
2018-02-26 - Bokslutskommuniké 2017
2017-11-14 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Acarix är ett diagnostikbolag. Bolaget har utvecklat en teknologi som möjliggör identifiering av kranskärlssjukdomar. Bolagets produkt är ett icke-invasivt test som sätts med en lapp på patienten för att analysera ljud från hjärtat. Idag innehas verksamhet främst inom den nordiska marknaden. Bolaget grundades under 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö.
2024-04-11 09:38:00

Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States.

The clinical study will collect data from 200 patients at the University of California, Davis, being assessed for chest pain in both the emergency department and outpatient cardiology clinic. The study will assess the potential improvement in cost-effectiveness, time savings, and reduction in side effects by utilizing the CADScor System to identify non-obstructive coronary artery disease in chest pain patients compared to traditional stress imaging tests. Patient enrollment for the study will commence in early Q2 2024, marking a crucial step forward in advancing the understanding of the CADScor System in various clinical workflows in the United States.

"For this study, we are evaluating the CADScor System to see if it offers patients an alternative to the standard stress test," stated Dr. Surabhi Madwhal Atreja, M.D., F.A.C.C., R.P.V.I., Health Sciences Clinical Professor, University of California, Davis and Principal Investigator. "Based on the findings, this study may be foundational for rapid assessment of non-obstructive CAD, streamlining ER processes, and establishing an algorithm at UC Davis Medical Center for the safe discharge of low-risk chest pain patients, saving time and avoiding unnecessary tests and radiation hazards for our patients."

"I am pleased to see the initiation of the first US study for the CADScor System, focused on potential efficiency improvements in the Clinic and Healthcare economic outcomes. This crucial step marks a significant milestone in establishing the system's real-world relevance in the United States healthcare system", stated Acarix President & CEO Aamir Mahmood. "The study not only underscores our commitment to advancing cardiovascular care, but we also believe this study will increase awareness of the CADScor System benefits in the United States."